+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 85Years
All Genders
ID07003386

Study on Galantamine From Lycoris Aurea to Improve Recovery After Acute Ischemic Stroke with Neurovascular Protection

Led by Shanghai Yueyang Integrated Medicine Hospital · Updated on 2025-09-16

66

Participants Needed

1

Research Sites

2 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of galantamine, a drug extracted from Lycoris aurea, in treating acute ischemic stroke. Despite high revascularization rates with current treatments like mechanical thrombectomy and thrombolytic therapy, many patients still face poor recovery due to microcirculatory dysfunction. This trial aims to assess how galantamine, known to improve cerebral blood flow and reduce inflammation, may enhance stroke-related outcomes, cognitive function, and Traditional Chinese Medicine syndrome symptoms. Participants will be randomly assigned to receive either standard treatment for acute ischemic stroke plus galantamine or standard treatment alone. Galantamine is given by intramuscular injection at a dose of 5.0 mg once daily, starting within 24 hours of hospital admission, and continuing for 10 days. The study follows participants for up to 90 days to monitor effects on neurological function, motor skills, cerebral blood flow, inflammatory markers, and quality of life. During the study, participants will undergo assessments including the National Institute of Health Stroke Scale NIHSS, motor function tests, brain imaging, inflammatory factor measurements, and cognitive evaluations at multiple time points baseline, 10 days, 30 days, and 90 days. Researchers will also evaluate functional independence and quality of life using established scales. The total participation duration extends to about three months, with ongoing safety monitoring and detailed analysis of treatment impact.

CONDITIONS

Brief Title

Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke

Research Team

C

Chunxiang Chen

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here